C M Clark1, J Li, C R Driver, S S Munsiff. 1. Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, New York 10007, USA. cclark@health.nyc.gov
Abstract
SETTING: New York City (NYC). OBJECTIVES: To examine the extent to which prior tuberculosis (TB) treatment, length of residence in the United States and other factors are associated with the occurrence of drug resistance among non-US-born persons in NYC. DESIGN: Cases were non-US-born persons diagnosed with TB in NYC from 1998-1999 and from 2001-2002, with an initial Mycobacterium tuberculosis isolate resistant to any first-line anti-tuberculosis drug. Controls were randomly selected from non-US-born persons whose isolates were susceptible to all first-line anti-tuberculosis drugs. RESULTS: Overall, cases with multidrug-resistant (MDR) TB were more likely to have had prior TB treatment; other drug resistance was not associated with prior TB treatment. In a multivariate model, the relationship between MDR-TB and prior treatment remained significant for non-US-born persons regardless of length of time in the U.S. CONCLUSIONS: The findings underscore the utility of monitoring trends in drug resistance among the non-US-born by time in the US and prior treatment to determine where or when drug resistance may be occurring.
SETTING: New York City (NYC). OBJECTIVES: To examine the extent to which prior tuberculosis (TB) treatment, length of residence in the United States and other factors are associated with the occurrence of drug resistance among non-US-born persons in NYC. DESIGN: Cases were non-US-born persons diagnosed with TB in NYC from 1998-1999 and from 2001-2002, with an initial Mycobacterium tuberculosis isolate resistant to any first-line anti-tuberculosis drug. Controls were randomly selected from non-US-born persons whose isolates were susceptible to all first-line anti-tuberculosis drugs. RESULTS: Overall, cases with multidrug-resistant (MDR) TB were more likely to have had prior TB treatment; other drug resistance was not associated with prior TB treatment. In a multivariate model, the relationship between MDR-TB and prior treatment remained significant for non-US-born persons regardless of length of time in the U.S. CONCLUSIONS: The findings underscore the utility of monitoring trends in drug resistance among the non-US-born by time in the US and prior treatment to determine where or when drug resistance may be occurring.
Authors: Adithya Cattamanchi; Raymund B Dantes; John Z Metcalfe; Leah G Jarlsberg; Jennifer Grinsdale; L Masae Kawamura; Dennis Osmond; Philip C Hopewell; Payam Nahid Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Leonela Villegas; Larissa Otero; Timothy R Sterling; Moises A Huaman; Patrick Van der Stuyft; Eduardo Gotuzzo; Carlos Seas Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240